Imagion Biosystems has lodged Pro-Rata Non-Renounceable Rights Issue: Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) with the Australian Securities Exchange.
View the Pro-Rata non-Renounceable Rights Issue announcement.
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance